Skip to content

ANEBULO PHARMACEUTICALS, INC.: 10-K filed 2025-09-29

What ANEBULO PHARMACEUTICALS, INC. reported in its annual report filed 2025-09-29 (fiscal FY 2025): 29 published measures, 58 facts as tagged in accession 0001493152-25-016015.

This filing

Form
10-K (annual report)
Filed
2025-09-29
Fiscal period
fiscal FY 2025
Accession
0001493152-25-016015 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANEBULO PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3012,145,616USD
At 2024-06-304,073,114USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-30487,688USD
At 2024-06-30260,583USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-3011,657,928USD
At 2024-06-303,812,531USD
At 2023-06-3010,601,350USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-3011,627,849USD
At 2024-06-303,094,200USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2025-06-30-8,484,763USD365
2023-07-01 to 2024-06-30-8,201,703USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-07-01 to 2025-06-30-6,349,687USD365
2023-07-01 to 2024-06-30-8,090,849USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-07-01 to 2025-06-3014,883,336USD365
2023-07-01 to 2024-06-30-62,354USD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-73,888,507USD
At 2024-06-30-65,403,744USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2025-06-3033,820,306shares365
2023-07-01 to 2024-06-3025,822,258shares366

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2025-06-3033,820,306shares365
2023-07-01 to 2024-06-3025,822,258shares366

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2025-06-30-0.25USD/shares365
2023-07-01 to 2024-06-30-0.32USD/shares366

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2025-06-30-0.25USD/shares365
2023-07-01 to 2024-06-30-0.32USD/shares366

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-07-01 to 2025-06-301,446,824USD365
2023-07-01 to 2024-06-30758,884USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2025-06-30-9,223,481USD365
2023-07-01 to 2024-06-30-8,308,755USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3011,962,506USD
At 2024-06-303,507,990USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-07-01 to 2025-06-30400,000USD365
2023-07-01 to 2024-06-30200,000USD366

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-06-30224,175USD
At 2024-06-30156,426USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2025-06-309,223,481USD365
2023-07-01 to 2024-06-308,308,755USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2025-06-304,299,941USD365
2023-07-01 to 2024-06-303,548,937USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3041,084,731shares
At 2024-06-3025,933,217shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-3085,505,349USD
At 2024-06-3069,190,341USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-06-30183,110USD
At 2024-06-30565,124USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-06-30263,513USD
At 2024-06-30104,157USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2025-06-304,923,540USD365
2023-07-01 to 2024-06-304,759,818USD366

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-07-01 to 2025-06-30382,014USD365
2023-07-01 to 2024-06-30151,230USD366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-07-01 to 2025-06-30-1,195USD365
2023-07-01 to 2024-06-309,260USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2025-06-30738,718USD365
2023-07-01 to 2024-06-30107,052USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-07-01 to 2025-06-3015,000,000USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2025-06-3067,749USD365
2023-07-01 to 2024-06-30-378,119USD366

Inspect the source

Entity
ANEBULO PHARMACEUTICALS, INC. / CIK 0001815974
Captured
2026-09-21T17:28:29.433Z
SEC response SHA-256
9b7fbc7aa6627d1ba25b78b2b6216133888564e8abee26c007f1576dedf9e9dd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001815974.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))